Hepion Pharmaceuticals (HEPA) Stock Climbs On Data

Hepion Pharmaceuticals HEPA Stock News

Positive Results In A Difficult-To-Treat Indication

While the results are early, only being studied in mouse and rat models to date, the data is promising. The truth of the matter is that there is a significant need for new therapeutic options in liver disease.

Although this condition is a highly prevalent one, there are absolutely no FDA approved therapies for treatment. Instead, doctors largely recommend diet and activity, leading to weight loss. After all, weight loss will lead to less fat in the liver.

Considering that there are no FDA approved treatment options for patients, it’s easy to see that NASH is a difficult-to-treat indication. Given these early results, it seems as though HEPA may be onto something meaningful here.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Continue Reading

Click Below To Continue Reading.

Pages: 1 2 3 4

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.